What's New

Continuing Education
Improving Outcomes for Patients with Myelofibrosis: A Case-based Analysis
John O. Mascarenhas, MD and Sandra Kurtin, PhD, ANP-C, AOCN, FAPO

Continuing Education
Beyond Ruxolitinib as the Frontline Standard of Care:
Current and Emerging Second-Line Therapies
Prithviraj Bose, MD; and Andrew Kuykendall, MD

Continuing Education
Defining Disease Response and Progression: Treatment Resistance, Failure and/or Loss of Response
Prithviraj Bose, MD; and John Mascarenhas, MD

FAQ
Other than cytopenias, what are signs that my patient is intolerant to ruxolitinib or a JAK inhibitor?
Sandra Kurtin, PhD, ANP-C, AOCN, FAPO

FAQ
What are the updates from ASH regarding new treatments or new data for patients with myelofibrosis?
John O. Mascarenhas, MD

What are MPNs?
What are Myeloproliferative neoplasms (MPNs)?

FAQ
Can we predict which patients will respond to a JAK inhibitor?
Andrew Kuykendall, MD and Prithviraj Bose, MD

FAQ
How would you define treatment success for your patients with myelofibrosis?
Andrew Kuykendall, MD and Prithviraj Bose, MD

FAQ
As a clinician, what should guide my decision on which second-line therapy to choose for my patients?
Prithviraj Bose, MD

FAQ
What key defining point should community providers be aware of when looking at patients considered to have failed ruxolitinib or have achieved only suboptimal response?
John Mascarenhas, MD
View all FAQs

MediCom Worldwide, Inc. Links

ManagingAML.com | ManagingMyeloma.com | ManagingMDS.com | ManagingLymphoma.com | PracticalOncologist.com | MediComWorldwide.com